BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen

Core Insights - BetterLife Pharma Inc. is focused on developing BETR-001, a non-hallucinogenic derivative of LSD, which is currently in preclinical and IND-enabling studies [1][2][3] - BETR-001 has advantages over traditional LSD, including the ability to administer full doses without inducing hallucinations and the lack of tolerance with repeated use [2][3] - The company plans to file for IND and begin human clinical trials in the second half of 2026, targeting treatments for Traumatic Brain Injury, cluster headaches, migraines, and various psychiatric disorders [3][4] Company Overview - BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on the development and commercialization of BETR-001 for neurological disorders [1][4] - BETR-001 is unique as it is unregulated and can be self-administered, with a synthesis patent that eliminates regulatory hurdles [3][4] - The company also owns a drug candidate for treating viral infections and is exploring strategic alternatives for its further development [4]